| Value | ₹100.0 Cr |
|---|---|
| Execution period | 18 months |
BSE filing, NSE: SANGAMIND. Summary written from the filing by ALFA Finder's alert engine.
Sangam (India) Ltd: key numbers
- Share price
- ₹611.00
- Market cap
- ₹3,070 Cr
- Revenue (annual)
- ₹3,235 Cr
- Net profit (annual)
- ₹82.60 Cr
- P/E (TTM)
- 20.2×Sector 33.3×
- Promoter holding
- 70.52%+0.00% QoQ
- FII holding
- 2.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sangam (India) Ltd
All →Sangam (India) Other Announcement
Sangam (India) Limited submitted its Monitoring Agency Report for the quarter ended September 2026. The report tracks utilization of Rs. 100.00 Crore raised via preferential warrant issuance.
Sangam (India) Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹1,045 Cr (+33.0% YoY), PAT ₹53 Cr (+130.9%), EBITDA margin 12.1%. H1 FY27 PAT already exceeds full FY26.
Sangam (India) Q2 FY27 Results: Net Profit ₹53.4 Cr, Up 131.2% YoY
Sangam (India) Ltd reported revenue from operations of ₹1,045 Cr (+33.0% YoY) and net profit of ₹53.4 Cr (+131.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹53.4 Cr · +131.2% YoY
Sangam (India) Board Meeting Date
Sangam India Ltd scheduled its board meeting for 4 November 2026 to approve unaudited Q2 results. No financial figures or decisions are reported in this prior intimation.
Sangam (India) Credit Rating
India Ratings upgraded Sangam (India)'s bank loan facilities to IND A/Stable from IND A-. Fresh bank facilities were also assigned the same rating.
Sangam (India) Annual General Meeting
Sangam (India) Limited announced the successful completion of a postal ballot, approving the appointment of Mr. Ranjan Jagetia as an Independent Director.
Other capital structure change announcements
All →Dr. Lal Pathlabs Capital Structure Change
Dr. Lal PathLabs will invest up to Rs 49.5 Crore in its wholly owned Dubai subsidiary, in tranches. Funds cover operations and further investment in Ghana's SHL.
- Value
- ₹49.50 Cr
- Execution
- Indicative completion by 31 March 2027, in tranches
Atul Capital Structure Change
Atul bought back 4,100 equity shares on 4 November 2026 for ₹2.09 Crore. Cumulative buyback utilisation stands at ₹10.82 Crore of ₹90 Crore earmarked.
- Value
- ₹2.09 Cr
Jenburkt Pharmaceuticals Capital Structure Change
Counter Cyclical Investments Private Limited acquired 4,608 equity shares of Jenburkt Pharmaceuticals Ltd through the open market. This acquisition increased the acquirer's total holding from 5.01% to 5.11%.
Premier Explosives Capital Structure Change
Rajasthan Global Securities sold 26,53,831 shares of Premier Explosives Ltd in the open market and offer. The sale reduced the non-promoter entity's stake from 5.90% to 0.08%.
Ola Electric Mobility Capital Structure Change
Promoter and Director Bhavish Aggarwal acquired 9,81,99,966 partly paid-up equity shares of Ola Electric Mobility Ltd for ₹1,590.84 Crore. The acquisition was executed via a rights issue allotment.
- Value
- ₹159.1 Cr
Ennature Bio Pharma Capital Structure Change
Ennature Bio Pharma listed its equity shares on NSE and BSE on 4 November 2026. The company brings its API, biopolymer and nutraceutical businesses to public markets.